Clinical Trials Logo

Hyperlipoproteinemia Type II clinical trials

View clinical trials related to Hyperlipoproteinemia Type II.

Filter by:

NCT ID: NCT02750527 Completed - Type 1 Diabetes Clinical Trials

Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany

Fr1dolin
Start date: September 2016
Phase:
Study type: Observational

This is a Pilot/ feasibility study for a population-based Screening in all children 2 to 6 years in Lower Saxony, Germany during the compulsory (U7 (from the age of 2) U7a, U8, U9) routine check-ups and any voluntary visits to the pediatricians office.

NCT ID: NCT02748057 Completed - Clinical trials for Hypercholesterolemia

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)

Start date: May 18, 2016
Phase: Phase 3
Study type: Interventional

The study will assess the safety and tolerability of Ezetimibe 10 mg+ Rosuvastatin 2.5 mg and Ezetimibe 10 mg+ Rosuvastatin 5.0 mg for up to 52 weeks in Japanese participants with hypercholesterolemia uncontrolled with monotherapy of Ezetimibe 10 mg or Rosuvastatin up to 5 mg.

NCT ID: NCT02729857 Completed - Healthy Clinical Trials

Postprandial Response After Intake of Meals With Different Fatty Acid Composition

Start date: March 2016
Phase: N/A
Study type: Interventional

The aim of the study is to understand more about how different fatty acids modulate postprandial lipid metabolism and inflammatory response.

NCT ID: NCT02722408 Completed - Hypercholesteremia Clinical Trials

Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)

Start date: June 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of Gemcabene in patients with HoFH on stable, lipid-lowering therapy.

NCT ID: NCT02709850 Completed - Clinical trials for Hypertriglyceridemia

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia

Start date: November 30, 2015
Phase: Phase 1
Study type: Interventional

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS ANGPTL3-LRx (ISIS 703802) given to healthy volunteer subjects with elevated triglycerides and subjects with familial hypercholesterolemia.

NCT ID: NCT02693548 Recruiting - Clinical trials for Familial Hypercholesterolaemia

The Spanish Familial Hypercholesterolaemia Cohort Study

SAFEHEART
Start date: January 2004
Phase:
Study type: Observational

SAFEHEART is a large, on-going registry study in molecularly defined patients with heterozygous FH treated in Spain.

NCT ID: NCT02651675 Terminated - Clinical trials for Homozygous Familial Hypercholesterolemia (HoFH)

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

Start date: March 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This first-in-human study is intended to evaluate the safety and preliminary effectiveness of AAV (Adeno-associated virus)-based liver-directed gene therapy in the treatment of adults with Homozygous Familial Hypercholesterolemia (HoFH).

NCT ID: NCT02624869 Completed - Clinical trials for Familial Hypercholesterolemia

Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)

HAUSER-OLE
Start date: September 10, 2016
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab when added to standard of care in children 10 to 17 years of age with familial hypercholesterolemia.

NCT ID: NCT02597127 Completed - Diabetes Clinical Trials

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

ORION-1
Start date: January 2016
Phase: Phase 2
Study type: Interventional

This study is a Phase II, placebo-controlled, double-blind, randomized trial in 480 participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (for example, diabetes and familial hypercholesterolemia) and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of ALN-PCSSC injection(s).

NCT ID: NCT02517944 Recruiting - Clinical trials for Familial Hypercholesterolemia - Heterozygous

MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)

CHOLCOEUR
Start date: November 2014
Phase: N/A
Study type: Observational [Patient Registry]

Patients with familial hypercholesterolemia (FH) at high cardiovascular risk may suffer from silent micro-infarctions (MI) before clinical coronary heart disease manifestations because of the lifetime exposure to elevated serum LDL-cholesterol levels. The study aims to demonstrate the higher prevalence of silent myocardial infarction in a population of asymptomatic patients with familial hypercholesterolemia at high cardiovascular risk in comparison to control patients using Cardiac Magnetic Resonance sequences of delayed gadolinium enhancement.